Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Non-Current Liabilities (2016 - 2026)

Myriad Genetics has reported Total Non-Current Liabilities over the past 16 years, most recently at $336.9 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 22.6% to $336.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $336.9 million through Dec 2025, up 22.6% year-over-year, with the annual reading at $336.9 million for FY2025, 22.6% up from the prior year.
  • Total Non-Current Liabilities was $336.9 million for Q4 2025 at Myriad Genetics, down from $353.6 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $440.6 million in Q2 2023 and troughed at $258.1 million in Q2 2022.
  • The 5-year median for Total Non-Current Liabilities is $315.2 million (2023), against an average of $331.0 million.
  • Year-over-year, Total Non-Current Liabilities tumbled 39.54% in 2022 and then surged 70.71% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $320.8 million in 2021, then decreased by 16.15% to $269.0 million in 2022, then rose by 17.17% to $315.2 million in 2023, then fell by 12.82% to $274.8 million in 2024, then increased by 22.6% to $336.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Total Non-Current Liabilities are $336.9 million (Q4 2025), $353.6 million (Q3 2025), and $287.3 million (Q2 2025).